BNP PARIBAS ASSET MANAGEMENT Holding S.A. Grows Position in Arcus Biosciences, Inc. (NYSE:RCUS)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 26.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 685,025 shares of the company’s stock after buying an additional 145,298 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.75% of Arcus Biosciences worth $12,933,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Nordea Investment Management AB grew its holdings in Arcus Biosciences by 26.3% in the 1st quarter. Nordea Investment Management AB now owns 259,372 shares of the company’s stock valued at $4,892,000 after buying an additional 53,944 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Arcus Biosciences by 11.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,594,609 shares of the company’s stock valued at $30,459,000 after purchasing an additional 158,094 shares during the period. Decheng Capital LLC purchased a new position in Arcus Biosciences during the fourth quarter worth about $16,613,000. Vanguard Group Inc. boosted its holdings in Arcus Biosciences by 4.2% in the 4th quarter. Vanguard Group Inc. now owns 4,680,716 shares of the company’s stock valued at $89,402,000 after purchasing an additional 186,898 shares during the last quarter. Finally, Alpha DNA Investment Management LLC grew its stake in shares of Arcus Biosciences by 11.6% in the 4th quarter. Alpha DNA Investment Management LLC now owns 28,690 shares of the company’s stock valued at $548,000 after buying an additional 2,974 shares during the period. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on RCUS. Barclays lowered their price objective on Arcus Biosciences from $35.00 to $25.00 and set an “overweight” rating for the company in a research report on Monday, July 8th. Truist Financial cut their price objective on Arcus Biosciences from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Monday, June 24th. Citigroup boosted their price objective on shares of Arcus Biosciences from $36.00 to $38.00 and gave the company a “buy” rating in a report on Monday, June 3rd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcus Biosciences in a research note on Friday, July 5th. Finally, Wedbush reissued an “outperform” rating and issued a $30.00 price target on shares of Arcus Biosciences in a research note on Thursday, May 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Arcus Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $38.11.

Arcus Biosciences Stock Down 2.3 %

NYSE:RCUS traded down $0.36 on Thursday, reaching $15.12. 68,690 shares of the company’s stock were exchanged, compared to its average volume of 769,176. The firm has a market capitalization of $1.38 billion, a price-to-earnings ratio of -4.87 and a beta of 0.90. Arcus Biosciences, Inc. has a 52-week low of $12.95 and a 52-week high of $25.47. The business has a fifty day moving average of $15.80 and a 200-day moving average of $16.56.

Arcus Biosciences (NYSE:RCUS) last announced its earnings results on Wednesday, May 8th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.97) by $0.92. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $28.77 million. Arcus Biosciences had a negative net margin of 97.47% and a negative return on equity of 40.98%. The firm’s revenue for the quarter was up 480.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.09) EPS. As a group, equities analysts anticipate that Arcus Biosciences, Inc. will post -3.07 earnings per share for the current year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.